{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:53:36Z","timestamp":1771494816575,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.blre.2011.09.002","type":"journal-article","created":{"date-parts":[[2011,9,29]],"date-time":"2011-09-29T01:11:34Z","timestamp":1317258694000},"page":"15-23","source":"Crossref","is-referenced-by-count":14,"title":["Optimal management of older patients with chronic lymphocytic leukemia: Some facts and principles guiding therapeutic choices"],"prefix":"10.1016","volume":"26","author":[{"given":"Tamar","family":"Tadmor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Polliack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2011.09.002_bb0005","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.09.002_bb0010","series-title":"SEER cancer statistics review, 1975\u20132008","author":"Howlader","year":"2010"},{"key":"10.1016\/j.blre.2011.09.002_bb0015","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","article-title":"Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0020","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","article-title":"Improving survival in patients with chronic lymphocytic leukemia (1980\u20132008): the Hospital Cl\u00ednic of Barcelona experience","author":"Abrisqueta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0025","first-page":"1","article-title":"Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80years or more. An ICLLSG study","author":"Bairey","year":"2011","journal-title":"Ann Hematol: Springer Berlin\/Heidelberg"},{"key":"10.1016\/j.blre.2011.09.002_bb0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4065\/81.8.1105","article-title":"Chronic lymphocytic leukemia: diagnosis and treatment","author":"Yee","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.blre.2011.09.002_bb0035","author":"Institute"},{"key":"10.1016\/j.blre.2011.09.002_bb0040","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3324\/haematol.2009.007849","article-title":"Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973\u20132003 in Sweden","author":"Kristinsson","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.09.002_bb0045","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/1097-0142(20010901)92:5<1325::AID-CNCR1454>3.0.CO;2-E","article-title":"Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data","author":"Zent","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.002_bb0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.09.002_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1182\/asheducation-2009.1.430","article-title":"Monoclonal B-cell lymphocytosis","author":"Rawstron","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2011.09.002_bb0060","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","article-title":"Treatment of elderly patients with chronic lymphocytic leukemia","author":"Eichhorst","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0070","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0075","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/ijc.22912","article-title":"Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964\u20132003","author":"Turesson","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2011.09.002_bb0080","series-title":"Hematology education: the education program for the 16th Congress of the European Hematology Association","first-page":"104","article-title":"Treatment of chronic lymphocytic leukemia in the elderly patients","author":"Eichhorst","year":"2011"},{"key":"10.1016\/j.blre.2011.09.002_bb0085","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.606386","article-title":"Chronic lymphocytic leukemia in less fit patients (\u201cSLOW-GO\u201d)","author":"Del Giudice","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0090","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/asheducation-2009.1.440","article-title":"State-of-the-art treatment of chronic lymphocytic leukemia","author":"Hallek","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2011.09.002_bb0095","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.1998.16.4.1582","article-title":"Comorbidity and functional status are independent in older cancer patients","author":"Extermann","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0100","series-title":"ASCO Educational Book","first-page":"268","article-title":"Chronic lymphocytic leukemia in the elderly: who should be treated?","author":"Zent","year":"2010"},{"key":"10.1016\/j.blre.2011.09.002_bb0105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.blre.2008.03.003","article-title":"New prognostic markers in chronic lymphocytic leukemia","author":"Moreno","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2011.09.002_bb0115","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1002\/cncr.25292","article-title":"Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia","author":"Shanafelt","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.002_bb0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.1989.tb07674.x","article-title":"Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults","author":"Catovsky","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2011.09.002_bb0125","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1182\/blood-2006-11-054916","article-title":"CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia","author":"Josefsson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0130","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis","author":"D\u00f6hner","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2011.02.002","article-title":"Importance of genetics in chronic lymphocytic leukemia","author":"Zenz","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2011.09.002_bb0140","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of Fludarabine, Cyclophosphamide, and Rituximab as initial therapy for chronic lymphocytic leukemia","author":"Keating","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0145","first-page":"219","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2011.09.002_bb0150","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","author":"D\u00f6hner","year":"2000","journal-title":"NEJM"},{"key":"10.1016\/j.blre.2011.09.002_bb0155","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0160","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","article-title":"Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997","author":"Grever","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2011.09.002_bb0165","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3109\/10428194.2011.568654","article-title":"Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach","volume":"52","author":"Zent","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0170","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","author":"Kr\u00f6ber","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0175","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0180","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","author":"Wierda","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0185","first-page":"717","author":"Badoux","year":"2005","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.09.002_bb0190","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.2008.18.1701","article-title":"Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment","author":"Wierda","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0195","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2011.09.002_bb0200","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of Fludarabine plus Cyclophosphamide compared with Fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2011.09.002_bb0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0210","first-page":"629","article-title":"No significant clinical benefit of first line therapy with Fludarabine (F) in comparison to Chlorambucil (Clb) in elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG)","author":"Eichhorst","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.09.002_bb0215","unstructured":"Smolej LBY, Spacek M, et al. Low-dose fludarabin and cyclophosphamide combined with rituximab in the treatment of elderly\/comorbid patients with chronic lymphocytic leukemia: project of Q-LITE of Czech CLL study group. Haematologica in press abstract 0105."},{"key":"10.1016\/j.blre.2011.09.002_bb0220","first-page":"1268","article-title":"Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy","author":"Marotta","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2011.09.002_bb0225","series-title":"Hematological Oncology","first-page":"247","article-title":"Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic leukaemia","author":"Forconi","year":"2008"},{"key":"10.1016\/j.blre.2011.09.002_bb0230","first-page":"699","author":"Mulligan","year":"2010","journal-title":"Blood, ASH Annu Meet Abstr"},{"key":"10.1016\/j.blre.2011.09.002_bb0235","first-page":"2466","article-title":"Low-dose Fludarabine and Cyclophosphamide combined with Rituximab in the treatment of elderly\/comorbid patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): preliminary results of Project Q-Lite by Czech CLL Study Group","author":"Smolej","year":"2010","journal-title":"ASH annu meet abstr"},{"issue":"4","key":"10.1016\/j.blre.2011.09.002_bb0240","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2008.17.2619","article-title":"Chemoimmunotherapy with low-dose Fludarabine and Cyclophosphamide and high dose Rituximab in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Foon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0245","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10428199909083391","article-title":"2-Chlorodeoxyadenosine (Cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia","author":"Robak","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0250","first-page":"2291","article-title":"Pentostatin, Cyclophosphamide, and Rituximab regimen in older patients with chronic lymphocytic leukemia","author":"Shanafelt","year":"2007"},{"issue":"11","key":"10.1016\/j.blre.2011.09.002_bb0255","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.2009.25.9630","article-title":"Comparison of Cladribine plus Cyclophosphamide with Fludarabine plus Cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)","volume":"28","author":"Robak","year":"2010","journal-title":"J Clin Oncol"},{"issue":"s1","key":"10.1016\/j.blre.2011.09.002_bb0260","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.clml.2011.02.006","article-title":"Chlorambucil\u2014still not bad: a reappraisal","volume":"11","author":"Catovsky","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2011.09.002_bb0265","unstructured":"Foa R, AA, Guarini A, et al. A phase II study of chlorambucil +rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia(CLL): induction phase results. Haemato-logica in press abstract-0532."},{"key":"10.1016\/j.blre.2011.09.002_bb0270","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/ehm.10.7","article-title":"Bendamustine: new perspective for an old drug in lymphoproliferative disorders","author":"Montillo","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2011.09.002_bb0280","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of Bendamustine compared with Chlorambucil in previously untreated patients with chronic lymphocytic leukemia","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0285","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1080\/10428190903166330","article-title":"Bendamustine\/mitoxantrone\/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia","author":"Weide","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"35","key":"10.1016\/j.blre.2011.09.002_bb0290","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with Chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0295","first-page":"2831","author":"Delmer","year":"2006","journal-title":"ASH annu meet abstr"},{"issue":"3","key":"10.1016\/j.blre.2011.09.002_bb0300","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3324\/haematol.11903","article-title":"High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy","volume":"93","author":"Dungarwalla","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2011.09.002_bb0305","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","article-title":"Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia","volume":"23","author":"Castro","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2011.09.002_bb0310","first-page":"4636","article-title":"Retrospective analysis of the experience with Rituximab and Methylprednisone in elderly patients with CLL","author":"Badoux","year":"2010","journal-title":"ASH annu meet abstr"},{"issue":"1","key":"10.1016\/j.blre.2011.09.002_bb0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00520-008-0452-y","article-title":"Complementary and alternative medicine in patients with chronic lymphocytic leukemia","volume":"17","author":"Hensel","year":"2009","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2011.09.002_bb0320","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-08-1511","article-title":"Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG","author":"Ghosh","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2011.09.002_bb0325","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2008.21.1284","article-title":"Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai Stage 0 to II chronic lymphocytic leukemia","author":"Shanafelt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0330","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","article-title":"The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo","author":"Lucas","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0335","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/clim.1999.4769","article-title":"Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, C-myc, Bcl-XL, NF-[kappa]B, and p53","author":"Han","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.blre.2011.09.002_bb0340","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1745-7254.2005.00081.x","article-title":"Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation1","author":"Liu","year":"2005","journal-title":"Acta Pharmacol Sin: Blackwell Publishing Asia"},{"key":"10.1016\/j.blre.2011.09.002_bb0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.178.1.111","article-title":"Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth","author":"Gururajan","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2011.09.002_bb0350","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2002-07-1984","article-title":"The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro","author":"Pepper","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2011.09.002_bb0355","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2010-07-295683","article-title":"Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia","author":"Shanafelt","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2011.09.002_bb0360","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/11587650-000000000-00000","article-title":"Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly","volume":"28","author":"Goede","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.blre.2011.09.002_bb0365","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1080\/1042819031000110991","article-title":"Conventional dose Fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia","author":"Shvidel","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2011.09.002_bb0370","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1200\/jco.2008.26.15_suppl.7048","article-title":"Subcutaneous low-dose alemtuzumab as first line therapy for elderly CLL patients with deletion of 17p","author":"Pitini","year":"2008","journal-title":"J Clin Oncol"},{"issue":"18S","key":"10.1016\/j.blre.2011.09.002_bb0375","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1200\/jco.2006.24.18_suppl.6602","article-title":"The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ferrajoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2011.09.002_bb0380","first-page":"563","article-title":"Long-term clinical remission of a patient with chronic lymphocytic leukemia using alternative treatment option: cottonseed oil (gossypol)","author":"WM.P","year":"2008","journal-title":"Phytomedicine"},{"key":"10.1016\/j.blre.2011.09.002_bb0385","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1021\/np100503q","article-title":"Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata","author":"Pan","year":"2010","journal-title":"J Nat Prod: Am Chem Soc"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X11000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T05:34:50Z","timestamp":1593063290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X11000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0268960X11000671"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2011.09.002","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}